MICROBIAL DPP4: NOVEL THERAPEUTIC TARGET FOR TYPE 2 DIABETES

Today, host DPP4 is an essential therapeutic target for managing type 2 diabetes. However, it's time to shift the focus toward microbial DPP4, suggests the author.

- M Balasubramanyam

In diabetes treatment, DPP4 inhibitors have been a vital focus, but now, there’s a fresh perspective on microbial DPP4. Let’s explore this emerging concept, its implications, and potential advancements in type 2 diabetes management.

INCRETIN-BASED THERAPIES

While the anti-diabetic therapies majorly include insulin secretagogues and insulin sensitizers, important advancements have occurred in the last few years in the field of diabetes treatment. The priority in the therapy of patients with diabetes is not only glycemic control per se but it now includes an overall management of risk factors with individualization of glycemic target.

The drugs which are used as second line agents (after metformin) in the therapeutic algorithm of type 2 diabetes mostly represented by the incretin-based therapies. This includes glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors.

DPP4 INHIBITOR ADVANTAGE